Lee Danner & Bass Inc. Purchases Shares of 652 Sanofi (NASDAQ:SNY)

Lee Danner & Bass Inc. bought a new position in Sanofi (NASDAQ:SNY) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 652 shares of the company’s stock, valued at approximately $31,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Synergy Asset Management LLC purchased a new position in Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. raised its holdings in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. Sunbelt Securities Inc. raised its holdings in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after acquiring an additional 313 shares during the period. Sierra Ocean LLC bought a new stake in Sanofi during the 4th quarter valued at $44,000. Finally, Versant Capital Management Inc bought a new position in shares of Sanofi in the fourth quarter worth $54,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

SNY stock opened at $56.90 on Monday. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12. The company has a market cap of $144.40 billion, a P/E ratio of 22.85, a PEG ratio of 1.01 and a beta of 0.58. The firm has a 50-day moving average of $54.55 and a 200 day moving average of $52.85. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

SNY has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday. They set a “neutral” rating and a $65.00 price target for the company. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.